Key Points
- Director Carolyn Taylor bought 1,415 shares of Tonix Pharmaceuticals at an average price of $10.55, increasing her position by 338.52% to 1,833 shares.
- Tonix Pharmaceuticals reported a loss of $2.93 per share in its latest quarterly results, missing analyst expectations, though revenue of $6.88 million came in above estimates.
- Analysts currently have a mixed view on TNXP, with one Strong Buy and one Sell rating, while MarketBeat shows a consensus target price of $22.00.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) Director Carolyn Taylor purchased 1,415 shares of the firm's stock in a transaction on Friday, June 12th. The shares were purchased at an average cost of $10.55 per share, with a total value of $14,928.25. Following the completion of the transaction, the director owned 1,833 shares of the company's stock, valued at approximately $19,338.15. The trade was a 338.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tonix Pharmaceuticals Stock Performance
TNXP stock opened at $11.52 on Tuesday. The firm has a market cap of $183.63 million, a price-to-earnings ratio of -0.80 and a beta of 1.67. The firm has a 50-day simple moving average of $12.99 and a two-hundred day simple moving average of $14.92. Tonix Pharmaceuticals Holding Corp. has a one year low of $10.03 and a one year high of $69.97.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($2.93) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The firm had revenue of $6.88 million for the quarter, compared to analysts' expectations of $6.13 million. As a group, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tonix Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada acquired a new position in Tonix Pharmaceuticals in the 1st quarter worth approximately $610,000. Geode Capital Management LLC increased its holdings in Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company's stock worth $6,305,000 after buying an additional 113,175 shares during the period. JPMorgan Chase & Co. acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $129,000. Legal & General Group Plc acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $25,000. Finally, New York State Common Retirement Fund acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $104,000. Institutional investors and hedge funds own 82.26% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. TD Cowen upgraded shares of Tonix Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, May 5th. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a report on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $22.00.
Check Out Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
